🇺🇸 FDA
Patent

US 6242473

Treatment and prevention of reactive oxygen metabolite-mediated cellular damage

expired A61KA61K31/00A61K31/33

Quick answer

US patent 6242473 (Treatment and prevention of reactive oxygen metabolite-mediated cellular damage) held by Maxim Pharmaceuticals, Inc. expires Mon May 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Maxim Pharmaceuticals, Inc.
Grant date
Tue Jun 05 2001 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/00, A61K31/33, A61K31/4045, A61K31/417